Security key
10806X102
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (BBIO)
CUSIP: 10806X102
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Total 13F shares
- 184,963,434
- Total 13F value
- $9,606,937,258
- Share change
- -3,590,755
- Put/Call ratio
- 16%
- SEC-reported price per share
- $51.94
- Number of holders
- 389
- Value change
- -$158,160,333
- Number of buys
- 218
- Number of sells
- 172
- Shares outstanding
- 195,328,418
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
389
Top holders
10
BBIO full security history
Ownership snapshot
Full 13F holder table
BridgeBio Pharma, Inc. SEC filings
BridgeBio Pharma, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
KKR Genetic Disorder L.P.
Disclosed value leader
VIKING GLOBAL INVESTORS LP
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
3/4/5
13F
Lead comparable stake: 7%
13D/G row: KKR Genetic Disorder L.P.
Showing 1-6 of 15 holder rows.
Quick read
KKR Genetic Disorder L.P. leads the comparable SEC ownership view at 7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens KKR Genetic Disorder L.P.'s linked filing trail.
Comparable ownership
Top 5
KKR Genetic Disorder L.P.
7%
PRICE T ROWE ASSOCIATES INC /MD/
1.1%
VIKING GLOBAL INVESTORS LP
9.5%
VANGUARD GROUP INC
8.4%
BlackRock, Inc.
7.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. |
13D/G
3/4/5
10%+ Owner
|
7%
|
$476,864,517
13,260,971 shares
|
-$215,760,000 | 12 May 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
1.1%
from 13D/G
|
$41,506,000
961,216 shares
|
— | 30 Jun 2025 |
| VIKING GLOBAL INVESTORS LP |
3/4/5
13F
10%+ Owner · Company
|
9.5%
|
$816,436,500
18,555,375 shares
|
— | 27 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
8.4%
|
$711,821,652
16,484,985 shares
|
— | 30 Jun 2025 |
| BlackRock, Inc. |
13F
Company
|
7.3%
|
$615,724,302
14,259,479 shares
|
— | 30 Jun 2025 |
| Kohlberg Kravis Roberts & Co. L.P. |
13F
Company
|
6.8%
|
$572,608,728
13,260,971 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
389
Shares
184,963,434
Rows available
389
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
357
Q3 2025 holders
389
Holder diff
32
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|